Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-10-17
2000-05-30
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424 9321, 435 691, 4353201, 435325, 435455, 435458, A61K 4800
Patent
active
060691344
ABSTRACT:
The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
REFERENCES:
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 5055400 (1991-10-01), Lo et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5532220 (1996-07-01), Lee et al.
Bacchett et al., Int. J. Oncol., 3(5), 1993.
Baker et al., "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53", Science, 249:912-915, Aug. 24, 1990.
Bandyopadhyay and Temin, "Expression of Complete Chicken Thymidine Kinase Gene Inserted in a Tetrovirus Vector," Molecular and Cellular Biology, 4(4):749-754, 1984.
Bargonetti et al., "Wild-Type but Not Mutant p53 Immunopurified Proteins Bind to Sequences Adjacent to the SV40 Origin of Replication", Cell, 65:1083-1092, Jun. 14, 1991.
Berkner, "Development of Adenovirus Vectors for the Expression of Heterologous Genes", BioTechniques, 6(7):616-629, 1988.
Blenis, "Signal transduction via the MAP kinases: Proceed at your own RSK", Proc. Natl. Acad. Sci. USA, 90:5889-5892, Jul. 1993.
Bowtell et al., "Comparison of Expression in Hemopoietic Cells by Retroviral Vectors Carrying Two Genes," , Journal of Virology, 62(7):2464-2473, 1988.
Brachman et al., "p53 Mutation Does Not Correlate with Radiosensitivity in 24 Head and Neck Cancer Cell Lines", Cancer Research, 53:3667-3669, Aug. 15, 1993.
Brown et al., "Increased Accumulation of p53 Protein in Cisplatin-Resistant Ovarian Cell Lines," Int. J. Cancer, 55:678-684, 1993.
Brown et al., "Mutant p53 Confers Cisplatin-sensitivity to Resistant Ovarian Tumour Cells with Elevated Wild-Type p53," Proc. Am. Assoc. Cancer Res., 34:355, #2116, 1993.
Capecchi, "Altering the Genome by Homologous Recombination", Science, 244:1288-1292, Jun. 16, 1989.
Casey et al., "Growth Suppression of Human Breast Cancer Cells by the Introduction of a Wild-Type p53 Gene," Oncogene, 6:1791-1797, 1991.
Casson et al., "p53 Gene Mutations in Barrett's Epithelium and Esophageal Cancer," Cancer Research, 51:4495-4499, 1991.
Chen et al., "Expression of Wild-Type p53 in Human A673 Cells Suppresses Tumorigenicity but Not Growth Rate," Oncogene, 6:1799-1805, 1991.
Chen et al., "Genetic Mechanisms of Tumor Suppression by the Human p53 Gene," Science, 250:1576-1580, 1990.
Cheng et al., "Suppression of Acute Lymphoblastic Leukemia by the Human Wild-Type p53 Gene", Cancer Research, 52:222-226, Jan. 1, 1992.
Clarke et al., "Thymocyte apoptosis induced by p53-dependent and independent pathways," Nature, 362-849-852, 1993.
Coleman and Turrisi, "Radiation and Chemotherapy Sensitizers and Protectors", Critical Reviews In Oncology/Hematology, 10(3):225-252, 1990.
Comings, "A General Theory of Carcinogenesis", Proc. Natl. Acad. Sci. USA, 70(12, Part I):3324-3328, Dec. 1973.
Comprehensive Textbook of Oncology, vol. 1, 2nd Ed., Williams & Wilkins, Publ., pp. 477, 527-536, 565-568, 590-594, 607-612.
Comprehensive Textbook of Oncology, vol. 2, 2nd. Ed., Williams & Wilkins, Publ., pp. 1098, 1138-1140, 1170, 1329, 1368, 1569-1572.
Conroy, "New Gene Therapy Cleared for Use Against Lung Cancer," Biotech Daily, pp. 3-4, Sep. 18, 1992.
Culver et al., Science, 256:1550-1552, 1992.
Cureil et al., 3, "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes", Human Gene Therapy, 147-154, 1992.
Debus et al., J. Cancer Res. Clin. Oncol., 116(Suppl Part 1):5-162, Abstract#A2.037.09, 1990.
Delauney et al., "A stable bifunctional antisense transcript inhibiting gene expression in transgenic plants", Proc. Natl. Acad. Sci. USA, 85:4300-4304, 1988.
Dialog Search Report dated Sep. 22, 1992.
Dialog Search Reports dated Aug. 7, 1992 and Feb. 26, 1993.
Diller et al., "p53 Functions as a Cell Cycle Control Protein in Osteosarcomas", Molecular and Cellular Biology, 10(11):5772-5781, Nov. 1990.
Donehower, "Tumor Suppressor Gene p53 and Apoptosis," Cancer Bulletin 46(2):161-166, 1994.
El Rouby et al., "p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression," Blood, 82(11):3452-3459, 1993.
El-Deiry et al., "WAF1, a Potential Mediator of p53 Tumor Suppression, " Cell, 75:817-825, 1993.
Fan et al., "The role of p53 in cell cycle arrest and apoptosis induced by multiple chemotherapeutic agents in Burkitt's lymphoma cells," Proceedings of the American Association for Cancer Research, 35:311, #1851, 1994.
Federal Register, vol. 47, No. 56, pp. Title-VI and i-iv, Mar. 23, 1982.
Feig et al., "Somatic Activation of ras .sup.K Gene in a Human Ovarian Carcinoma", Science, 223:698-701, 1984.
Finkel et al., "Activation of ras Genes in Human Tumors Does Not Affect Localization, Modification, or Nucleotide Binding Properties of p21", Cell, 37:151-158, 1984.
Foreman et al., 4(3) Title Unknown, Bone Marrow Transportation, 1990.
Fornace Jr., "Induction by radiation of mammalian genes associated with growth-arrest and apoptosis, and the role for the p53 tumor suppressor in their regulation,"Proceedings of the American Association for Cancer Research, 35:681-682, 1994.
Friedman, "Gene Therapy of Cancer through Restoration of Tumor-Suppressor Functions?", Cancer Supplement, 70(6):1810-1817, Sep. 15, 1992.
Fritsche et al., "Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents," Oncogene, 8:307-318, 1993.
Fritsche et al., "Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents," published erratum, Oncogene, 8(9):2605, 1993.
Fujiwara et al., "A Retroviral Wild-type p53 Expression Vector Penetrates Human Lung Cancer Spheriods and Inhibits Growth by Inducing Apoptosis," Cancer Research, 53:4129-4133, 1993.
Fujiwara et al., "Induction of Chemosensitivity in Human Lung Cancer Cells in vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene", Cancer Research, 54:2287-2291, May 1, 1994.
Goyette et al., "Progression of Colorectal Cancer Is Associated with Multiple Tumor Suppressor Gene Defects but Inhibition of Tumorigenicity Is Accomplished by Correction of Any Single Defect via Chromosome Transfer," Molecular and Cellular Biology, 12(3):1387-1395, 1992.
Graham et al., 7 Title Unknown, Methods in Molecular Biology, Gene Transfer and Expression Protocols, Ch. 11, pp. 109-128, 1991.
Griep and Heiner, "Antisense Myc sequences induce differentiation of F9 cells", Proc. Natl. Acad. Sci. USA, 85:6806-6810, 1988.
Gudkov et al., "Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interatction cytotoxic drugs, from human topoiosmerase II cDNA", Proc. Natl. Acad. Sci. USA, 90:3231-3235, Apr. 1993.
Gunning et al., "A human .beta.-actin expression vector system directs high-level accumulation of antisense transcripts", Proc. Natl. Acad. Sci. USA, 84:4831-4835, 1987.
Gusterson et al., "Expression of p53 in Premalignant and Malignant Squamous Epithelium," Oncogene, 6:1785-1798, 1991.
Harper et al, "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," Cell, 75;805-816, 1993.
Hecht et al., "Comparison of wildtype and mutated p53 protein expression induced by UV irradiation of cultured cells," FASEB Journal8:A667, #3870, 1994.
Hinds et al., Cell Growth and Differen
Fujiwara Toshiyoshi
Grimm Elizabeth A.
Mukhopadhyay Tapas
Owen-Schaub Laurie B.
Roth Jack A.
Board of Regents , The University of Texas System
Nguyen Dave Trong
Stanton Brian R.
LandOfFree
Methods and compositions comprising DNA damaging agents and p53 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions comprising DNA damaging agents and p53, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions comprising DNA damaging agents and p53 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910497